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The term ‘cardiovascular disease’ (CVD) encompasses a wide spectrum of diseases—including ischaemic heart disease 
(IHD), congenital structural heart disease and various 
inherited arrhythmias and cardiomyopathies—each 
of which has its own aetiology and pathogenesis. 
IHD continues to be a leading cause of morbidity and 
mortality worldwide and its incidence is increasing in 
the developing world.1 It is estimated that 17.5 million 
people die each year from CVD, accounting for 31% 
of all deaths worldwide; more than three-quarters 
of these deaths occur in low- and middle-income 
countries.1 
Our understanding of the pathogenesis of CVD 
as a whole, and IHD in particular, has changed over 
the years and many risk factors have been identified. 
Risk scores can predict a person’s cardiovascular risk 
over 10 years and identify those at high risk for whom 
intensive preventive measures would help.2 Many new 
modalities of treatment, both pharmacological and 
interventional, have been established as the mainstay 
of treatment over the last few years. However, most 
of these advances seek to treat or prevent so-called 
modifiable risk factors. It is important to note that 
many of these risk factors have a genetic predisposition, 
thereby limiting the extent to which they can be 
modified. A genetic basis to most disease processes 
is now widely accepted and genetic associations have 
been described for hypertension, obesity, hypercho-
lesterolaemia and diabetes.3 Understandably, attention 
is now focused towards understanding the genetic 
basis of CVD and IHD in particular. 
Perhaps one of the most remarkable discoveries of 
the last century is our understanding of genes and our 
genetic make-up. Indeed, it is not surprising that most 
of the Nobel prizes awarded for medicine have been 
in the field of genetic research.4 The importance of a 
strong family history as a risk factor for IHD has been 
engrained into the minds of most medical students. 
However, despite our advances in knowledge, our 
understanding of the genes behind CVD is still limited, 
apart from a few genetic lineages. Interestingly, more 
than 100 different cardiovascular loci have been 
described in the human genome.3 However, the effects 
of these loci are still unknown as most studies have 
only shown associations.3 
The current issue of SQUMJ includes two 
studies investigating the association of certain genes 
with cardiovascular risk factors. In the first study, 
Rizvi et al. assessed the association of angiotensin 
converting enzyme and glutathione S-transferase gene 
polymorphisms with body mass index (BMI) among 
hypertensive North Indians; they found that these 
gene polymorphisms were not associated with BMI 
but were significantly associated with hypertension.5 
Interestingly, other genes that control the renin-
angiotensin-aldosterone system (RAAS) have also 
been implicated in the pathogenesis of hypertension.6 
The RAAS is responsible for salt and water balance 
and consequently blood pressure. Therefore, it is 
understandable that changes in genes controlling this 
system could affect blood pressure. In the second 
study, Al-Balushi et al. observed the frequencies of 
Arg16Gly, Gln27Glu and Thr164Ile polymorphisms 
in the adrenergic β-2 receptor (ADRB2) gene in the 
Omani population.7 It is interesting to note that the 
frequency of these genetic variants in the Omani 
population was similar to that seen in Caucasian 
populations.7 This demonstrates that there does not 
appear to be an ethnic variation in the polymorphism 
of this gene. Leineweber et al. have suggested that 
variations in this gene do not directly cause disease 
processes.8 However, other researchers have noted that 
variations can affect patients’ responses to drugs that 
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target ADRB2, such as those used in the treatments of 
asthma and hypertension.9,10
Where do we go from here? Despite our under-
standing of the genetic basis of these conditions, we 
are still a long way from applying this knowledge to 
either the prevention or treatment of IHD. Human 
genetic engineering is still a very contentious and 
divisive topic. However, an enhanced understanding 
of these genes and the genetic basis of various risk 
factors would still enable us to identify high-risk 
populations, to ensure that high-intensity prophylactic 
and primary prevention measures can be undertaken. 
Oncology is one such field where the identification of 
people with high-risk alleles can lead to preventative 
surgery, although the benefit of such a course of action 
is controversial.11 Many candidate gene studies have 
also been performed to assess asthma susceptibility; 
however, no significant correlation has been found 
between ADRB2 gene mutations and response to 
asthma medications.12,13 In the cardiovascular field, 
identifying high-risk patients through genetic studies 
has been helpful for those susceptible to developing 
cardiomyopathies and channelopathies causing cer-
tain arrhythmias. Prophylactic interventions, such 
as implantable cardiac defibrillators, can now help 
prevent sudden cardiac death in high-risk patients 
with known pathogenic mutations.14 
Within the field of IHD, the benefits of genetic 
studies are yet to be seen. There was a considerable 
amount of interest 20 years ago, following the 
identification of certain alleles that were found to be 
associated with CVD.15 However, despite significant 
research in this field, longitudinal studies have failed 
to show any prognostic value for these gene variants 
in risk-stratifying patients. Furthermore, we are still 
no closer to producing risk models for predicting 
cardiovascular risk using genetic information.16 One 
of the main reasons for this is due to the multifactorial 
nature of IHD pathogenesis. There is a significant 
degree of interaction between the environment and the 
genetic make-up of an individual; as a result, whether 
individuals with a particular genotype eventually 
contract the disease is another matter.
Our present understanding seems to suggest that 
it is not one gene on its own that leads to CVD, but 
rather an interaction between the effects of various 
genes.16,17 Single nucleotide polymorphisms (SNPs) 
are single base changes in an individual’s genome 
that differ from the usual base at that location. The 
estimated relative risks associated with SNPs are 
very small and individually confer between 1.0–1.2 
times the risk of developing the associated disease—a 
person would therefore need to have dozens or even 
hundreds of at-risk SNPs to double or triple the risk of 
a complex disease such as IHD.17 Thus, we would need 
to test a large number of candidate SNPs and conduct 
longitudinal long-term follow-ups before we could 
obtain any meaningful results for clinical application. 
The elucidation of epigenetic factors is also critical 
for our understanding of disease predisposition in 
IHD.18 Epigenetics refers to heritable changes in 
gene expression that do not require changes in the 
DNA sequence and which are instead mediated by 
chromatin-based mechanisms. These changes explain 
why individuals with similar genetic backgrounds and 
risk factors for a particular disease can have different 
clinical manifestations and responses to therapy.  
Does this mean that despite the initial excitement 
we have hit the proverbial ‘brick wall’? Are these gene 
association studies useless? In our opinion, we should 
not be pessimistic about the future of genetics in the 
field of CVD and IHD. We are still a long way from 
fully understanding the true effect of multiple gene 
variants. Genetic testing is still in its infancy and 
various genome-wide association studies form the 
foundation of future research. The 1,000 Genomes 
Project and the Encyclopedia of DNA Elements 
(ENCODE) project are two worldwide initiatives 
that will certainly help improve our understanding 
of genes.19,20 The ENCODE project was established 
in 2003 by the National Human Genome Research 
Institute in the USA with the aim of studying the 
functional elements in the human genome, their tissue 
distribution and the ways in which changes in DNA 
sequences affect gene function.20 The 1,000 Genomes 
Project is an international programme launched in 
2008 tasked with cataloguing variations in human 
genomes across different ethnicities.19 
Pharmacogenetics is another field in which our 
knowledge of genes can help us to manage diseases. 
Genes can affect a person’s response to medications 
and thereby affect the overall outcome of treatment. 
For example, mutations in the cytochrome P-450 
enzyme gene, CY2C19, are associated with decreased 
responsiveness to the antiplatelet agent clopidogrel 
and an increased likelihood of complications following 
coronary stenting.21 Identifying patients with these 
mutations can lead to tailored therapy. However, at 
the present moment, studies investigating genotype-
personalised antiplatelet therapy have failed to show 
any prognostic benefit.22,23 This may be due to the 
process of stent thrombosis and the complexity of 
antiplatelet responses. Nevertheless, this is still a 
promising aspect of genetic testing which should be 
studied more extensively.24 
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O’Donnell et al. summarised the pathway needed 
for the application of CVD genomics knowledge: 
large-scale cross-sectional studies are required to 
show the associations of candidate genes or mutations 
with particular cardiovascular risk factors and 
longitudinal studies are required to show causation.3 
From there, risk prediction models can be generated.3 
However, this would not be easy as most CVD risk 
factors are polygenic, with environmental factors also 
playing a significant role. Studies of this nature are 
time-consuming, expensive and difficult to conduct 
due to the sheer number of patients required to 
achieve statistical significance. Once a causative effect 
is found, then preventative interventions can be 
studied. In addition, one must be aware of the legal 
and privacy issues that come with genetic testing as 
well as the potential emotional and social effects of 
predictive genetic testing, especially in asymptomatic 
individuals.25,26 All centres that offer genetic testing 
should have well-trained genetic counsellors who 
can provide patients with an objective explanation of 
the potential benefits and risks of testing.27 Another 
potential drawback of genetic testing is the likely 
misuse of sensitive information for insurance and 
employment purposes. As such, the USA government 
has passed legislation that bans the discrimination of 
individuals based on their genetic make-up.27
In conclusion, the impact of the field of genetics 
in CVD is extensive and promising. It is also fairly 
complicated in view of the various risk factors and the 
important role of environmental and lifestyle factors. 
Multiple genetic variations have an association with 
CVD, but the advent of routine genetic testing for 
patients with this condition is still far-removed. At 
present, perhaps the greatest benefit of genetic testing 
is in pharmacogenetics, whereby genotyping would 
help us in identifying patients who are less likely to 
respond to particular drugs in order to tailor their 
therapies accordingly. Furthermore, it is imperative 
that clinicians and scientists be aware of the various 
social, ethical and moral implications of genetic testing 
before advising these tests for their patients. 
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